2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Ris-Rez: new trials by email Literature Review of Ris-Rez trials Research Report on Ris-Rez
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations HS-20093 for Injection, Adebrelimab Injection - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 76 | 2026-10-08 | 2026-10-23 |
| A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) Ris-Rez, G-CSF - Sarcoma | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 64 | 2026-06-22 | 2026-10-01 |
Carcinoma, Non-Small-Cell Lung (1) · Sarcoma (1)
GlaxoSmithKline (1) · Hansoh BioMedical R&D Company (1)
Canada (1) · China (1) · France (1) · Israel (1) · Japan (1) · United Kingdom (1) · United States (1)
2025 (1)